Quick Answer
Gain Therapeutics, Inc. reported R&D Expense of $10.21 million for fiscal year 2025.
Gain Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $10.21M | -5.4% |
| 2024 | $10.79M | -6.3% |
| 2023 | $11.52M | +37.5% |
| 2022 | $8.38M | +16.9% |
| 2021 | $7.16M | +217.1% |
| 2020 | $2.26M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $2.85M | +8.7% | +3.3% |
| June 30, 2025 | $2.76M | -37.8% | +22.2% |
| March 31, 2025 | $2.26M | -10.0% | -13.9% |
| September 30, 2024 | $2.62M | +10.7% | -40.9% |
| June 30, 2024 | $4.44M | +11.3% | +77.0% |
| March 31, 2024 | $2.51M | -10.2% | +5.9% |
| September 30, 2023 | $2.37M | +20.5% | -40.6% |
| June 30, 2023 | $3.99M | +54.4% | +42.9% |
- Gain Therapeutics, Inc. showed a decrease of -5.4% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2025 period, Gain Therapeutics, Inc.’s r&d expense has grown by 352.1% (from $2.26 million to $10.21 million).
- The most recent figure is from Gain Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: